30 related articles for article (PubMed ID: 18619723)
1. The effect of tributyltin on human eosinophilic [correction of eosinophylic] leukemia EoL-1 cells.
Sroka J; Włosiak P; Wilk A; Antonik J; Czyz J; Madeja Z
Cell Mol Biol Lett; 2008; 13(1):67-73. PubMed ID: 17965975
[TBL] [Abstract][Full Text] [Related]
2. Novel
Alsouqi A; Kleinberger J; Werner TS; Awan R; Chopra S; Rea B; Aggarwal N; Yatsenko SA; Farah R; Bailey NG
Haematologica; 2023 Nov; 108(11):3181-3185. PubMed ID: 37102594
[No Abstract] [Full Text] [Related]
3. Eosinophilia characterized by a rare CCT6B mutation and responsive to tyrosine kinase inhibition: Case report and literature review.
Singh A; Baron J; Singh N; Peringeth G; Wang ES
Leuk Res Rep; 2021; 16():100279. PubMed ID: 34820261
[TBL] [Abstract][Full Text] [Related]
4. Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL.
Li B; Zhang G; Li C; Li R; Lu J; He Z; Wang Q; Peng Z; Wang J; Dong Y; Zhang C; Tan JQ; Bahri N; Wang Y; Duan C
Oncotarget; 2017 Sep; 8(39):64984-64998. PubMed ID: 29029406
[TBL] [Abstract][Full Text] [Related]
5. Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.
Sadovnik I; Lierman E; Peter B; Herrmann H; Suppan V; Stefanzl G; Haas O; Lion T; Pickl W; Cools J; Vandenberghe P; Valent P
Exp Hematol; 2014 Apr; 42(4):282-293.e4. PubMed ID: 24407160
[TBL] [Abstract][Full Text] [Related]
6. Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.
Hochhaus A; le Coutre PD; Kantarjian HM; Baccarani M; Erben P; Reiter A; McCulloch T; Fan X; Novick S; Giles FJ
J Cancer Res Clin Oncol; 2013 Dec; 139(12):1985-93. PubMed ID: 24057647
[TBL] [Abstract][Full Text] [Related]
7. Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.
Li B; Zhang G; Li C; He D; Li X; Zhang C; Tang F; Deng X; Lu J; Tang Y; Li R; Chen Z; Duan C
PLoS One; 2012; 7(4):e34912. PubMed ID: 22523564
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.
Valent P; Gleich GJ; Reiter A; Roufosse F; Weller PF; Hellmann A; Metzgeroth G; Leiferman KM; Arock M; Sotlar K; Butterfield JH; Cerny-Reiterer S; Mayerhofer M; Vandenberghe P; Haferlach T; Bochner BS; Gotlib J; Horny HP; Simon HU; Klion AD
Expert Rev Hematol; 2012 Apr; 5(2):157-76. PubMed ID: 22475285
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia.
Ramchandren R; Schiffer CA
Biologics; 2009; 3():205-14. PubMed ID: 19707409
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.
Verstovsek S
Leuk Res; 2009 May; 33(5):617-23. PubMed ID: 19013641
[TBL] [Abstract][Full Text] [Related]
11. Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors.
Ishihara K; Kaneko M; Kitamura H; Takahashi A; Hong JJ; Seyama T; Iida K; Wada H; Hirasawa N; Ohuchi K
Int Arch Allergy Immunol; 2008; 146 Suppl 1():7-10. PubMed ID: 18504399
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
13. EoL-1, a human eosinophilic cell line.
Mayumi M
Leuk Lymphoma; 1992 Jun; 7(3):243-50. PubMed ID: 1477652
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
Baumgartner C; Gleixner KV; Peter B; Ferenc V; Gruze A; Remsing Rix LL; Bennett KL; Samorapoompichit P; Lee FY; Pickl WF; Esterbauer H; Sillaber C; Superti-Furga G; Valent P
Exp Hematol; 2008 Oct; 36(10):1244-53. PubMed ID: 18619723
[TBL] [Abstract][Full Text] [Related]
15. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.
Ishihara K; Kitamura H; Hiraizumi K; Kaneko M; Takahashi A; Zee O; Seyama T; Hong J; Ohuchi K; Hirasawa N
Biochem Biophys Res Commun; 2008 Feb; 366(4):1007-11. PubMed ID: 18086564
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
